Elaborate ligand-based modeling reveal new migration inhibitory factor inhibitors

Journal of Molecular Graphics and Modelling

Volumn 42, Issue , 2013, Pages 104-114

  Al Sha'Er, Mahmoud A ^a   Vanpatten, Sonya ^b   Al Abed, Yousef ^b   Taha, Mutasem O ^c  

^a ZARQA UNIVERSITY   (Jordan)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c UNIVERSITY OF JORDAN   (Jordan)

Author keywords

In silico screening; Migration inhibitory factor; Pharmacophore modeling; Quantitative structure activity relationship

Indexed keywords

IN-SILICO SCREENING; MIGRATION INHIBITORY FACTORS; MULTIPLE LINEAR REGRESSION ANALYSIS; NATIONAL CANCER INSTITUTE; PHARMACOPHORE MODELING; PHYSICO-CHEMICAL DESCRIPTORS; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP; RECEIVER OPERATING CHARACTERISTIC CURVES;

BINDING ENERGY; DISEASES; LIGANDS; LINEAR REGRESSION; MOLECULAR GRAPHICS; OPTIMIZATION; PHARMACODYNAMICS;

COMPUTATIONAL CHEMISTRY;

MACROPHAGE MIGRATION INHIBITION FACTOR;

ARTICLE; BIOLOGICAL ACTIVITY; COMPUTER MODEL; GENETIC ALGORITHM; PHARMACOPHORE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

BINDING SITES; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; INFLAMMATION; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MODELS, MOLECULAR; NEOPLASMS; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; ROC CURVE;

EID: 84877345693     PISSN: 10933263     EISSN: 18734243     Source Type: Journal    
DOI: 10.1016/j.jmgm.2013.03.003     Document Type: Article

References (66)

1. J.A. Baugh, and R. Bucala Macrophage migration inhibitory factor Critical Care Medicine 30 2002 S27 S35
2. J. Bernhagen, T. Calandra, R.A. Mitchell, S.B. Martin, K.J. Tracey, W. Voelter, K.R. Manogue, A. Cerami, and R. Bucala MIF is a pituitary-derived cytokine that potentiates lethal endotoxemia Nature 365 1993 756 759
3. B. Bloom, and B. Bennett Mechanism of a reaction in vitro associated with delayed-type hypersensitivity Science 153 1966 80 82
4. N. Petrovsky, L. Socha, D. Silva, A.B. Grossman, C. Metz, and R. Bucala Macrophage migration inhibitory factor exhibits a pronounced circadian rhythm relevant to its role as a glucocorticoid counter-regulator Immunology and Cell Biology 81 2003 137 143
5. S.C. Donnelly, and R. Bucala Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease Molecular Medicine Today 3 1997 502 507
6. E. Rosengren, R. Bucala, P. Aman, L. Jacobsson, G. Odh, C.N. Metz, and H. Rorsman The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction Molecular Medicine 2 1996 143 149
7. R.A. Mitchell, and R. Bucala Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF) Seminars in Cancer Biology 10 2000 359 366
8. T. Hagemann, S.C. Robinson, R.G. Thompson, K. Charles, H. Kulbe, and F.R. Balkwill Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis Molecular Cancer Therapeutics 6 2007 1993 2002
9. A. Mikulowska, C.N. Metz, R. Bucala, and R. Holmdahl Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice Journal of Immunology 158 1997 5514 5517
10. L.R. McLean, Y. Zhang, H. Li, Y.-M. Choi, Z. Han, R.J. Vaz, and Y. Li Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site Bioorganic and Medicinal Chemistry Letters 20 2010 1821 1824
11. M. Orita, S. Yamamoto, N. Katayama, and S. Fujita Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors Current Pharmaceutical Design 8 2002 1297 1317
12. M. Orita, S. Yamamoto, N. Katayama, M. Aoki, K. Takayama, Y. Yamagiwa, N. Seki, H. Suzuki, H. Kurihara, H. Sakashita, M. Takeuchi, S. Fujita, T. Yamada, and A. Tanaka Coumarin and chromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography Journal of Medicinal Chemistry 44 2001 540 547
13. L.R. McLean, Y. Zhang, H. Li, Y.M. Choi, Z. Han, R.J. Vaz, and Y. Li Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site Bioorganic and Medicinal Chemistry Letters 20 2010 1821 1824
14. F. El Turk, B. Fauvet, H.O. -Sakouhi, A. Lugari, S. Betzi, P. Roche, X. Morelli, and H.A. Lashuel An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity Bioorganic and Medicinal Chemistry 18 2010 5425 5440
15. Y. Fukunishi Structure-based drug screening and ligand-based drug screening with machine learning Combinatorial Chemistry & High Throughput Screening 12 2009 397 408
16. J. Garai, V. Molnár, D. Eros, L. Orfi, and T. Lóránd MIF tautomerase inhibitor potency of α,β-unsaturated cyclic ketones International Immunopharmacology 7 2007 1741 1746
17. R.A. Beeley, and N.C. Sage GPCRs: an update on structural approaches to drug discovery Targets 2 2003 19 25
18. G. Klebe Virtual ligand screening: strategies, perspectives and limitations Drug Discovery Today 11 2006 580 594
19. H. Steuber, M. Zentgraf, C. Gerlach, C.A. Sotriffer, A. Heine, and G.J. Klebe Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions Molecular Biology 363 2006 174 187
20. M.T. Stubbs, S. Reyda, F. Dullweber, M. Moller, G. Klebe, D. Dorsch, W. Mederski, and H. Wurziger pH-Dependent binding modes observed in trypsin crystals: lessons for structure-based drug design ChemBioChem 3 2002 246 249
21. M.A. DePristo, P.I.W. de Bakker, and T.L. Blundell Heterogeneity and inaccuracy in protein structures solved by X-ray crystallography Structure 12 2004 831 838
22. F. El-Turk, M. Cascella, H.O. -Sakouhi, R.L. Narayanan, L. Leng, R. Bucala, M. Zweckstetter, U. Rothlisberger, and H.A. Lashuel The conformational flexibility of the carboxy terminal residues 105-114 is a key modulator of the catalytic activity and stability of macrophage migration inhibitory factor Biochemistry 47 2008 10740 10756
23. M.O. Taha, Y. Bustanji, M.A.S. Al-Ghussein, M. Mohammad, H. Zalloum, I.M. Al-Masri, and N. Atallah Pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening reveal potent glycogen synthase kinase-3β inhibitory activities for cimetidine, hydroxychloroquine and gemifloxacin Journal of Medicinal Chemistry 51 2008 2062 2077
24. M.O. Taha, N. Atallah, A.G. Al-Bakri, C. Paradis-Bleau, H. Zalloum, K. Younis, and R.C. Levesque Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening Bioorganic and Medicinal Chemistry 16 2008 1218 1235
25. M.O. Taha, Y. Bustanji, A.G. Al-Bakri, M. Yousef, W.A. Zalloum, I.M. Al-Masri, and N. Atallah Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening Journal of Molecular Graphics and Modelling 25 2007 870 884
26. I.M. Al-masri, M.K. Mohammad, and M.O. Taha Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening ChemMedChem 3 2008 1763 1779
27. M.O. Taha, L.A. Dahabiyeh, Y. Bustanji, H. Zalloum, and S. Saleh Combining ligand-based pharmacophore modeling, QSAR analysis and in-silico screening for the discovery of new potent hormone sensitive lipase inhibitors Journal of Medicinal Chemistry 51 2008 6478 6494
28. A. Al-Nadaf, G. Abu Sheikha, and M.O. Taha Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent β-secretase inhibitory leads Bioorganic and Medicinal Chemistry 18 2010 3088 3115
29. A.M. Abu-Hammad, and M.O. Taha Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors Journal of Chemical Information and Modeling 49 2009 978 996
30. R. Abu Khalaf, G. Abu Sheikha, Y. Bustanji, and M.O. Taha Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration European Journal of Medical Chemistry 45 2010 1598 1617
31. M.A. Al-Sha'er, and M.O. Taha Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay European Journal of Medical Chemistry 45 2010 4316 4330
32. M.A. Al-Sha'er, and M.O. Taha Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors Journal of Chemical Information and Modeling 50 2010 1706 1723
33. CATALYST 4.11 Users' Manual, Accelrys Software Inc., San Diego, CA, 2005.
34. H.O. -Sakouhi, F. El-Turk, B. Fauvet, M.-K. Cho, D.P. Karpinar, D.L. Roy, M. Dewor, T. Roger, J. Bernhagen, T. Calandra, M. Zweckstetter, and H.A. Lashuel Identification and characterization of novel classes of macrophage migration inhibitory factor (MIF) inhibitors with distinct mechanisms of action Journal of Biological Chemistry 285 2010 26581 26598
35. J. Garai1, and T. Lóránd Macrophage migration inhibitory factor (MIF) tautomerase inhibitors as potential novel anti-inflammatory agents: current developments Current Medicinal Chemistry 16 2009 1091 1114
36. N.M. Dagia, D.V. Kamath, P. Bhatt, R.D. Gupte, S.S. Dadarkar, L.F.G. Agarwal, A. Chetrapal-Kunwar, S. Balachandran, S. Srinivasan, J. Bose, K. Pari, C. B-Rao, S.S. Parkale, P.K. Gadekar, A.H. Rodge, N. Mandrekar, R.A. Vishwakarma, and S. Sharma A fluorinated analog of ISO-1 blocks the recognition and biological function of MIF and is orally efficacious in a murine model of colitis European Journal of Pharmacology 607 2009 201 212
37. i) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction Biochemical Pharmacology 22 1973 3099 3108
38. J. Sutter, O. Güner, R. Hoffmann, H. Li, and M. Waldman O.F. Güner, Pharmacophore Perception, Development, and Use in Drug Design 2000 International University Line La Jolla, CA 501 511
39. Y. Kurogi, and O.F. Güner Pharmacophore modeling and three dimensional database searching for drug design using catalyst Current Medicinal Chemistry 8 2001 1035 1055
40. K. Poptodorov, T. Luu, T. Langer, and R. Hoffmann R.D. Hoffmann, Methods and Principles in Medicinal Chemistry. Pharmacophores and Pharmacophores Searches; vol. 2 2006 Wiley-VCH Weinheim, Germany 17 47
41. H. Li, J. Sutter, and R. Hoffmann O.F. Güner, Pharmacophore Perception, Development, and Use in Drug Design, 2000 International University Line La Jolla, CA 173 189
42. I.B. Bersuker, S. Bahçeci, and J.E. Boggs O.F. Güner, Pharmacophore Perception, Development, and Use in Drug Design 2000 International University Line La Jolla, CA 457 473
43. R. Fischer The Principle of Experimentation Illustrated by a Psycho-Physical ExpeHafner Publishing Co. 8th ed. 1966 Hafner Publishing New York (chapter II)
44. CERIUS2 LigandFit User Manual (version 4.10), Accelrys Inc., San Diego, CA (2005) 3-48.
45. CERIUS2, QSAR Users' Manual, version 4.10, Accelrys Inc., San Diego, CA (2005) 43-88, 221-235, 237-250.
46. J. Kirchmair, P. Markt, S. Distinto, G. Wolber, and T. Langer Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection - What can we learn from earlier mistakes? Journal of Computer-Aided Molecular Design 22 2008 213 228
47. J.J. Irwin, and B.K. Shoichet ZINC - a free database of commercially available compounds for virtual screening Journal of Chemical Information and Computer Science 45 2005 177 182
48. N. Triballeau, F. Acher, I. Brabet, J.-P. Pin, and H.-O. Bertrand Virtual screening workflow development guided by the "receiver operating characteristic" curve approach, application to high-throughput docking on metabotropic glutamate receptor subtype 4 Journal of Medicinal Chemistry 48 2005 2534 2547
49. D.F. Veber, S.R. Johnson, H.Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple Molecular properties that influence the oral bioavailability of drug candidates Journal of Medicinal Chemistry 45 2002 2615 2623
50. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Advanced Drug Delivery Reviews 46 2001 3 26
51. A. Dios, R.A. Mitchell, B. Aljabari, J. Lubetsky, K. O'Connor, H. Liao, P.D. Senter, K.R. Manogue, E. Lolis, C. Metz, R. Bucala, D.J. Callaway, and Y. Al-Abed Journal of Medicinal Chemistry 45 2002 2410 2416
52. J.H. Van Drie Pharmacophore discovery - lessons learned Current Pharmaceutical Design 9 2003 1649 1664
53. R.P. Sheridan, and S.K. Kearsley Why do we need so many chemical similarity search methods? Drug Discovery Today 7 2002 903 911
54. L.F. Ramsey, and W.D. Schafer The Statistical Sleuth 1st ed. 1997 Wadsworth Publishing Company Belmont, CA
55. O.O. Clement, and A.T. Mehl O.F. Guner, Pharmacophore perception, development, and use in drug design. IUL Biotechnology Series 2000 International University Line La Jolla, CA 71 84
56. M.L. Verdonk, L. Marcel, V. Berdini, M.J. Hartshorn, W.T.M. Mooij, C.W. Murray, R.D. Taylor, and P. Watson Virtual screening using protein-ligand docking: avoiding artificial enrichment Journal of Chemical Information and Computer Science 44 2004 793 806
57. J.B. Lubetsky, A. Dios, J. Han, B. Aljabari, B. Ruzsicska, R. Mitchell, E. Lolis, and Y. Al-Abed The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents Journal of Biological Chemistry 277 2002 24976 32482
58. C. Gerlach, M. Smolinski, H. Steuber, C.A. Sotriffer, A. Heine, D.G. Hangauer, and G. Klebe Thermodynamic inhibition profile of a cyclopentyl and a cyclohexyl derivative towards thrombin: the same but for different reasons Angewandte Chemie International Edition 46 2007 8511 8514
59. A.M. Davis, S.A. St-Gallay, and G.J. Kleywegt Limitations and lessons in the use of X-ray structural information in drug design Drug Discovery Today 13 2008 831 841
60. P.D. Senter, Y. Al-Abed, C.N. Metz, F. Benigni, R.A. Mitchell, J. Chesney, J. Han, C.G. Gartner, S.D. Nelson, G.J. Todaro, and R. Bucala Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites PNAS 99 2002 144 149
61. K.F. Cheng, and Y. Al-Abed Critical modifications of the ISO-1 scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity Bioorganic and Medicinal Chemistry Letters 16 2006 3376 3379
62. L.G. Warren, D.T. Do, P.B. Kelley, A. Nicholls, and D.S. Warren Essential considerations for using protein-ligand structures in drug discovery Drug Discovery Today 17 2012 1270 2128
63. Z. Cournia, L. Leng, S. Gandavadi, X. Du, R. Bucala, and W.L. Jorgensen Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening Journal of Medicinal Chemistry 52 2009 416 424
64. M. Winner, J. Meier, S. Zierow, B.E. Rendon, G. Chrichlow, R. Riggs, R. Bucala, L. Leng, N. Smith, E. Lolis, J.O. Trent, and R.A. Mitchell A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells Cancer Research 68 2008 7253 7257
65. T.A. Soares, R.D. Lins, T.P. Straatsma, and J.M. Briggs Internal dynamics and ionization states of the macrophage migration inhibitory factor: comparison between wild-type and mutant forms Biopolymers 65 2002 313 323
66. L. Xu, Y. Li, L. Li, S. Zhou, and T. Hou Understanding microscopic binding of macrophage migration inhibitory factor with phenolic hydrazones by molecular docking, molecular dynamics simulations and free energy calculations Molecular BioSystems 8 2012 2260 2273